1. Home
  2. KNSL vs PRAX Comparison

KNSL vs PRAX Comparison

Compare KNSL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kinsale Capital Group Inc.

KNSL

Kinsale Capital Group Inc.

N/A

Current Price

$365.88

Market Cap

9.2B

Sector

Finance

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$308.71

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KNSL
PRAX
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2B
9.6B
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
KNSL
PRAX
Price
$365.88
$308.71
Analyst Decision
Buy
Strong Buy
Analyst Count
10
15
Target Price
$455.40
$572.13
AVG Volume (30 Days)
266.5K
331.9K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
0.27%
N/A
EPS Growth
21.77
N/A
EPS
21.65
N/A
Revenue
$1,873,987,000.00
N/A
Revenue This Year
$6.46
N/A
Revenue Next Year
$8.77
$6,395.88
P/E Ratio
$17.24
N/A
Revenue Growth
18.04
N/A
52 Week Low
$341.06
$26.70
52 Week High
$512.76
$354.87

Technical Indicators

Market Signals
Indicator
KNSL
PRAX
Relative Strength Index (RSI) 37.91 43.30
Support Level $345.03 $290.36
Resistance Level $400.98 $322.32
Average True Range (ATR) 10.10 18.62
MACD -1.18 -5.00
Stochastic Oscillator 9.53 26.55

Price Performance

Historical Comparison
KNSL
PRAX

About KNSL Kinsale Capital Group Inc.

Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: